Tianjin Pharmaceutical Da Ren Tang Group Corporation Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Tianjin Pharmaceutical Da Ren Tang Group Corporation Stock Forecast and Price Target
The average price target for Tianjin Pharmaceutical Da Ren Tang Group Corporation's stock set by recognized analysts recently is $44.28, which would result in a potential upside of approximately 48.94% if it reached this mark. The estimation is based on a high estimate of $44.28 and a low estimate of $44.28. Even if you are not interested in T14 stock, you should still be aware of its competitors.
48.94% Upside
Tianjin Pharmaceutical Da Ren Tang Group Corporation Fair Value Forecast for 2023 - 2025 - 2030
In the last zero years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Price has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $26.25 – an increase of 100.00%. The Tianjin Pharmaceutical Da Ren Tang Group Corporation forecast is for Fair Value to reach $22.24 or grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥43.60 | Buy/Sell | ¥56.49 | 23.85% |
600436 Stock Forecast | Zhangzhou Pientzehuang Pharmac... | Outperform |
18
|
¥229.63 | Buy/Sell | ¥302.86 | 36.49% |
000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥51.56 | Buy/Sell | ¥65.39 | 26.45% |
1093 Stock Forecast | CSPC Pharmaceutical Group | Outperform |
18
|
HK$6.01 | Buy/Sell | HK$9.50 | 54.24% |
600085 Stock Forecast | Beijing Tongrentang | Outperform |
16
|
¥43.10 | Buy/Sell | ¥61.18 | 50.81% |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Revenue has increased by 24.92%, going from $6.60B to $8.25B. In the next year, analysts are expecting an increase in Revenue, predicting it will reach $10.25B – an increase of 24.21%. The Tianjin Pharmaceutical Da Ren Tang Group Corporation forecast is for Revenue to reach $10.18B or grow by 23.35%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥24.76 | Buy/Sell | ¥33.57 | 25.77% |
000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥54.57 | Buy/Sell | ¥65.95 | 15.43% |
600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.56 | Buy/Sell | ¥32.49 | -34.29% |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Dividend per Share has grown, increasing from $0.30 to $1.12 – an increase of 273.33%. According to 2 prominent analysts, Tianjin Pharmaceutical Da Ren Tang Group Corporation's Dividend per Share will fall by 69.64% in the next year, reaching $0.34. By 2030, professionals believe that Tianjin Pharmaceutical Da Ren Tang Group Corporation's Dividend per Share will decrease by 39.65%, reaching $0.68 – a concerning trend for the company.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
002294 Stock Forecast | Shenzhen Salubris Pharmaceutic... | Buy |
18
|
¥27.78 | Buy/Sell | ¥35.65 | 33.19% |
300146 Stock Forecast | Byhealth | Buy |
15
|
¥16.96 | Buy/Sell | ¥26.39 | 41.51% |
000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
600518 Stock Forecast | Kangmei Pharmaceutical | - |
6
|
¥1.90 | Buy/Sell | ¥25.97 | -100.00% |
002262 Stock Forecast | Jiangsu Nhwa Pharmaceutical Co... | Buy |
18
|
¥23.17 | Buy/Sell | ¥31.34 | 33.79% |
600380 Stock Forecast | Joincare Pharmaceutical Group ... | Buy |
18
|
¥11.61 | Buy/Sell | ¥14.72 | 26.79% |
Tianjin Pharmaceutical Da Ren Tang Group Corporation EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's EBITDA has grown, increasing from $658.57M to $783.89M – a growth of 19.03%. The next year looks promising for Tianjin Pharmaceutical Da Ren Tang Group Corporation, with analysts predicting EBITDA of $1.33B – an increase of 69.35%. Over the next seven years, experts anticipate that Tianjin Pharmaceutical Da Ren Tang Group Corporation's EBITDA will grow at a rate of 68.74%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
900904 Stock Forecast | Shanghai Shenqi Pharmaceutical... | - |
13
|
$6.46 | Buy/Sell | $0.00 | -100.00% |
600867 Stock Forecast | Tonghua Dongbao Pharmaceutical | Buy |
18
|
¥10.11 | Buy/Sell | ¥14.25 | 48.17% |
600062 Stock Forecast | China Resources Double-Crane P... | Buy |
16
|
¥21.19 | Buy/Sell | ¥26.00 | 8.54% |
Tianjin Pharmaceutical Da Ren Tang Group Corporation EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's EBIT has grown by 21.83%, from $551.04M to $671.32M. For the next year, analysts are expecting EBIT to reach $1.58B – an increase of 134.84%. Over the next seven years, experts predict that EBIT will grow by 122.65%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
603858 Stock Forecast | Shandong Buchang Pharmaceutica... | - |
18
|
¥16.85 | Buy/Sell | ¥0.00 | -100.00% |
000623 Stock Forecast | Jilin Aodong Pharmaceutical Gr... | Buy |
16
|
¥15.28 | Buy/Sell | ¥0.00 | 48.36% |
6826 Stock Forecast | Shanghai Haohai Biological Tec... | Outperform |
18
|
HK$39.35 | Buy/Sell | HK$65.08 | 65.39% |
Tianjin Pharmaceutical Da Ren Tang Group Corporation EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last zero years, Tianjin Pharmaceutical Da Ren Tang Group Corporation's EPS has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach $1.75 – an increase of 100.00%. The Tianjin Pharmaceutical Da Ren Tang Group Corporation forecast is for EPS to reach $1.48 or grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
600422 Stock Forecast | KPC Pharmaceuticals,Inc | Buy |
18
|
¥19.32 | Buy/Sell | ¥28.00 | 44.93% |
002773 Stock Forecast | Chengdu Kanghong Pharmaceutica... | Buy |
11
|
¥17.32 | Buy/Sell | ¥24.00 | -100.00% |
600535 Stock Forecast | Tasly Pharmaceutical Group | Hold |
18
|
¥15.89 | Buy/Sell | ¥0.00 | -8.12% |